▶ 5-AMINO-1MQ · SUBTOPIC · MECHANISM

5-AMINO-1MQ Mechanism

For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.

MECHANISM OF ACTION

5-Amino-1-methylquinolinium iodide. Selective inhibitor of nicotinamide N-methyltransferase (NNMT). Blocking NNMT raises intracellular NAD+ and SAM pools, theorized to drive lipolysis and improve insulin sensitivity in adipose tissue.

PHARMACOKINETIC HALF-LIFE

Reported half-life for 5-AMINO-1MQ: Short plasma half-life (oral bioavailable). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.

MECHANISM CATEGORIES

5-AMINO-1MQ is tagged in 2 mechanism categories on GIGARESEARCH. Each category aggregates the broader pharmacology of related compounds.

▶ METABOLIC REGULATION

Compounds acting on metabolic regulation include incretin agonists (GLP-1, GIP, glucagon), AMPK activators (MOTS-c), and GHRH analogs that drive lipolysis (tesamorelin). The shared therapeutic target is metabolic dysfunction underlying obesity, type 2 diabetes, NAFLD, and the broader cardiometabolic syndrome.

▶ LONGEVITY

The longevity category includes compounds acting on canonical aging-biology pathways: sirtuins (NAD+-dependent deacylases), mitochondrial function and biogenesis, cellular senescence, autophagy, and the AMPK/mTOR axis. NAD+ and its precursors are the most-studied longevity compounds; MOTS-c (mitochondrial-derived peptide) is an emerging category.

MECHANISTIC OUTCOMES IN LITERATURE

The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with GIGARESEARCH evidence grades. Grades reflect study quality and replication, not clinical recommendation.

▶ NNMT enzymatic inhibition (in vitro)GRADE A

Well-characterized small-molecule inhibitor of nicotinamide N-methyltransferase.

▶ Adipose mass reduction (DIO mice)GRADE B

Neelakantan et al. 2017 reported reduced adipose mass in diet-induced obese mice without changes in food intake.

▶ Human metabolic outcomesGRADE D

No completed human Phase 2/3 trials. Most evidence preclinical.

CITED LITERATURE

Kraus D, Yang Q, Kong D, et al.. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 2014. link
Neelakantan H, Vance V, Wetzel MD, et al.. Selective NNMT inhibitor (5-amino-1MQ) reduces adiposity in DIO mice. J Med Chem 2017. link

◀ 5-AMINO-1MQ OVERVIEW DOSING LITERATURE ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19